Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.
This study investigated whether the naturally occurring copper-binding peptide GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) could reduce Alzheimer's disease (AD)-related pathology in a transgenic mouse model. Male and female 5xFAD mice — a well-established preclinical model of AD — were treated with intranasal GHK-Cu three times per week from 4 to 7 months of age, with a C57BL/6J background strain as context. The researchers assessed behavioral outcomes, amyloid plaque burden, and neuroinflammation markers. The study found that treated mice showed delayed cognitive impairment compared to untreated controls, along with reductions in amyloid plaques and lower levels of MCP1-associated inflammation in the frontal cortex and hippocampus. The authors suggest these findings justify further investigation of GHK-Cu as a potential AD therapeutic. Key limitations include the exclusively preclinical (animal) nature of the work — results in transgenic mouse models do not reliably predict outcomes in humans — and the fact that 5xFAD mice represent an aggressive, artificially accelerated form of amyloid pathology that may not fully reflect the complexity of human AD.
Why this grade: The study was conducted entirely in a transgenic mouse model (5xFAD), with no human subjects or clinical data, providing no direct evidence of efficacy or safety in humans.
Alzheimer's disease (AD) is a complex neurodegenerative disease and a leading cause of morbidity and mortality. Efforts to find disease modifying treatments have met with limited success. The naturally occurring peptide GHK (glycyl-L-histidyl-L-lysine), in its Cu-bound form, supports angiogenesis, remodeling, and tissue repair, has anti-inflammatory and antioxidant properties, and has been shown to improve cognitive performance in aging mice. These features raised the question of whether GHK-Cu could alleviate neurodegeneration observed in AD. Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age. Results showed that intranasal GHK-Cu treatment delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation levels in the frontal cortex and hippocampus. These observations provide the rationale for conducting additional studies to investigate the potential of GHK-Cu peptide as a promising treatment for AD.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.